膳食肌醇补充对胰岛素抵抗及妊娠期糖尿病预防效果的随机对照试验研究方案
本研究为单中心、开放标签随机对照试验方案,拟纳入160名孕11-13+6周健康单胎孕妇,随机分为干预组(每日4000 mg肌醇+400 mcg叶酸)和对照组(每日400 mcg叶酸),干预至孕26-28周。主要结局为孕26-28周75 g口服葡萄糖耐量试验诊断的妊娠期糖尿病发生率,次要结局包括空腹血糖、糖化血红蛋白、胰岛素抵抗水平及饮食治疗或胰岛素治疗的妊娠期糖尿病发生率。
要点
- 评估孕期肌醇补充能否降低妊娠期糖尿病发生率。
- 干预组每日4000 mg肌醇+400 mcg叶酸,对照组仅叶酸。
- 主要结局为孕26-28周OGTT诊断的GDM发生率。
核心结论
- 该试验旨在为孕期肌醇补充降低妊娠期糖尿病发生率提供证据。
研究设计与样本
- 单中心、开放标签、随机对照试验,计划纳入160名孕11-13+6周健康单胎孕妇,干预组和对照组各80名。
关键数值与推荐
- 干预组每日给予4000 mg肌醇和400 mcg叶酸,对照组每日仅给予400 mcg叶酸,均从孕11-13+6周至孕26-28周。
- 主要结局为孕26-28周根据75 g口服葡萄糖耐量试验结果诊断的妊娠期糖尿病发生率。
- 次要结局包括空腹血糖、糖化血红蛋白、胰岛素抵抗水平(HOMA-IR和Matsuda指数)、饮食治疗的妊娠期糖尿病及需胰岛素治疗的糖尿病发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gestational diabetes mellitus (GDM) is defined as impaired glucose tolerance with onset or first recognition during pregnancy, which is characterized by an increased insulin resistance. Gestational diabetes mellitus is associated with pregnancy-related maternal and fetal morbidity (both antenatal and perinatal). Myo-inositol has been suggested to improve insulin resistance in women with polycystic ovary syndrome. The aim of this study is to examine the impact of myo-inositol supplementation during pregnancy on the incidence of gestational diabetes mellitus. METHODS: We will conduct a single-center, open-label, randomized controlled trial. A total of 160 healthy pregnant women with singleton pregnancy at 11-13+6 weeks of gestation will be randomly allocated in two groups: intervention group (N = 80) and control group (N = 80). The intervention group will receive myo-inositol and folic acid (4000 mg myo-inositol and 400 mcg folic acid daily) from 11 to 13+6 weeks of gestation until 26-28 weeks of gestation, while the control group will receive folic acid alone (400 mcg folic acid daily) for the same period of time as intervention group. The primary outcome will be gestational diabetes incidence rate at 26-28 weeks of gestation, according to the results of a 75 g oral glucose tolerance test held at 26-28 weeks of gestation. The secondary outcomes will include fasting blood glucose levels, glycated hemoglobin levels, insulin resistance level (evaluated by homeostasis model assessment of insulin resistance and Matsuda Index), and incidence rate of diet-treated gestational diabetes and diabetes requiring insulin therapy at 26-28 weeks of gestation. DISCUSSION: This trial will provide evidence for the effectiveness of myo-inositol supplementation during pregnancy in reducing the incidence of gestational diabetes mellitus. TRIAL REGISTRATION: ISRCTN registry: ISRCTN16142533 . Registered on 9 March 2017.
引用
- Asimakopoulos G, Pergialiotis V, Anastasiou E, et al. Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32646482. doi:10.1186/s13063-020-04561-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。